bryan johnson tirzepatide on X: "I'm starting a new longevity protocol: microdosing Tirzepatide, a dual GLP-1/GIP receptor agonist. Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve UTMB Tirzepatide Anti-Aging Trial

#ObesityMedicine #MetabolicHealth #GLP1 #PersonalizedMedicine #Telehealth #EvidenceBasedMedicine #HealthcareInnovation #PreventiveHealth #Amply #LiveWellLiveAmply To view or add a comment, sign in The Royal Society of Medicine is hosting an event for healthcare professionals about weight loss treatments, including GLP-1 drugs, and how they are reshaping both clinical practice and public discourse around people living with obesity To view or add a comment, sign in The needle era of obesity medicine may be ending

I would say number one, for osteoarthritis, high-quality, randomized evidence shows that substantial weight loss with semaglutide can significantly reduce knee pain and improve function

Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates

Patients on semaglutide who are not experiencing adequate appetite control may benefit from a provider discussion about switching to tirzepatide